Type One Energy is betting that its lean approach to fusion power will get a power plant on the grid faster, and investors have rewarded it with $200 million.

ArkeaBio, a Boston-based agricultural bioscience company, has raised $7 million in Series A1 funding. The round was co-led by Breakthrough Energy Ventures and AgriZeroNZ, bringing the company's total funding to over $40 million. ArkeaBio is developing a vaccine to reduce methane emissions from cattle. Led by CEO Frank Wooten, the company uses targeted rumen microbiology and immunological targeting to suppress methane-producing archaea whilst preserving beneficial gut microbes. The funds will support continued R&D, farmer pilot programmes, and general operations. ArkeaBio currently conducts animal studies and plans to expand into field programmes in 2026-2027 ahead of commercial deployment.

ArkeaBio, a Boston-based startup developing a vaccine to reduce livestock methane emissions, has raised $15 million in a Series A2 round led by AgriZeroNZ and supported by Breakthrough Energy. The company has reduced its headcount by approximately a third to focus on commercialisation in New Zealand. CEO Frank Wooten said the firm is concentrating on its initial market and product to ensure sufficient runway to reach critical milestones. The vaccine prompts cows' immune systems to produce antibodies that interfere with methanogens, microbes that produce methane in the rumen. ArkeaBio's first product aims for a 10-15% methane reduction, though the company is targeting higher reductions in future iterations. The firm plans to submit a regulatory application next year and expects to generate revenues in 2028.